文献速递泌尿生殖技术与安全PET

前列腺癌PET影像组学研究的方法学质量与临床转化评估

Bridging the Gap from "Paper" to "Patient": An Overview and Quality Assessment of PET/CT-Based Radiomics for Prostate Cancer Using the Updated RQS 2.0.
PubMed 文献 · Acad Radiol · 2026-06-18

本研究应用RQS 2.0与RRL框架系统评价前列腺癌PET影像组学研究。共纳入39项研究,平均RQS为14.59±3.90(40.4%±11.0%),所有研究处于RRL 4–7级,无研究达到8级及以上。结论认为当前方法学质量为中等,尚不成熟于临床转化。

要点

  • 前列腺癌PET影像组学研究总体方法学质量为中等(RQS%约40%),临床转化成熟度不足。
  • 自动分割、多中心验证、前瞻性临床验证是当前主要欠缺环节,审稿与科研设计时应重点考量。
  • 不同显像模态、研究主题、示踪剂类型间RQS差异无统计学意义,选择时不应仅据此判断质量。

核心结论

  • 前列腺癌PET影像组学研究方法学质量为中等,平均RQS为14.59±3.90,对应RQS%为40.4%±11.0%。
  • 所有研究处于RRL 4–7级,无研究达到RRL 8级或以上,表明临床转化成熟度不足。

研究设计与样本

  • 共纳入39项研究,采用RQS 2.0工具评价,计算总RQS、RQS%及RRL等级。
  • 评价者间一致性为总RQS的ICC=0.89,RRL分级的加权κ=0.41。

诊断标准与关键数值

  • 总RQS评分者间一致性极好(ICC=0.89),RRL分级一致性中等(加权κ=0.41)。
  • 不同影像模态、研究主题、示踪剂类型间RQS差异均无统计学意义(所有P>0.05)。
  • 研究质量随年份发表时间未见显著提升。
  • 自动分割、多中心验证、前瞻性临床验证为已识别的关键欠缺领域。

临床应用与阅片要点

  • 日常科研评价中可参考RQS 2.0与RRL框架系统评估前列腺癌PET影像组学研究的方法学质量与转化成熟度。
  • 阅片/报告相关临床决策引用影像组学结论时须注意:当前证据多缺乏多中心和前瞻性验证支持。
  • 不同示踪剂或显像设备来源的影像组学研究质量无显著差异,不能仅凭技术路线判断证据等级。

局限性

  • 所纳入研究均未达到RRL 8级及以上,高等级临床转化证据完全缺失。
  • RRL分级评价者间一致性仅中等(加权κ=0.41),分级判断可能存在一定主观性。
  • 亚组分析未发现质量差异,但未报告各亚组具体样本量分布,可能影响统计效能解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To apply the updated Radiomics Quality Score (RQS 2.0) and the Radiomics Readiness Level (RRL) framework to systematically evaluate the methodological quality and clinical translation maturity of Positron-emission tomography (PET)-based radiomics studies in prostate cancer (PCa).

MATERIALS AND METHODS: Two independent researchers conducted a systematic literature search for studies published between January 1, 2015, and October 31, 2025. Included PET-based PCa radiomics studies were evaluated using the RQS 2.0 tool. The total RQS, RQS percentage (RQS%), and RRL grade were calculated. Subgroup analyses were performed based on different study characteristics. Inter-rater agreement was assessed using the intraclass correlation coefficient (ICC) and weighted Kappa statistic.

RESULTS: A total of 39 studies were included. The mean total RQS score was 14.59 ±3.90, corresponding to an RQS% of 40.4% ± 11.0%. Inter-rater agreement was excellent for the total RQS (ICC = 0.89) and moderate for RRL grading (weighted κ = 0.41). Subgroup analyses indicated no statistically significant differences in RQS scores across different imaging modalities, research topics, or tracer types (all P > 0.05). Study quality did not show a significant improvement over time. All studies were at RRL levels 4-7, and no study reached RRL level 8 or higher. Notable deficiencies were identified in key areas, including automated segmentation, multicenter validation, and prospective clinical validation.

CONCLUSION: Current PET-based radiomics studies in PCa demonstrate moderate methodological quality but remain insufficiently mature for clinical translation. Future research should strengthen validation rigor, promote open science practices, and conduct fairness assessments to facilitate clinical translation.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Bian, Yang, Wang, et al. Bridging the Gap from "Paper" to "Patient": An Overview and Quality Assessment of PET/CT-Based Radiomics for Prostate Cancer Using the Updated RQS 2.0. Acad Radiol. 2026. PMID: 42315441. doi:10.1016/j.acra.2026.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。